Diana Rafael

TL;DR: Nanotechnology-based drug delivery systems (nano-DDS) emerged as a promising approach to circumvent the limitations of conventional formulations and to treat drug resistance, opening the hypothesis for new developments in this area.

TL;DR: An in vitro cancer stem cell model to study the effects of active targeting using antibody-labeled micelles containing chemotherapeutic agent is designed and should allow future testing of various drug/carrier platforms before the clinical phase.

TL;DR: This review discusses recent progress and pertinent limiting factors related to the use of siRNA-s as efficient protein-specific "silencing" agents, focusing on targeted delivery not only to cells of interest, but to the proper intracellular destination.

TL;DR: The dynamic cross-talk between the adhesion-related proteins such as E-cadherin and the EMT-related transcription factors, with special focus on TWIST, will be discussed here, with the aim of finding a suitable biological pathway to be used as potential target for cancer therapy.

TL;DR: Findings suggest AKT2 as a promising target for future anti-cancer therapies at three important levels: Epithelial-to-mesenchymal transition (EMT) reversion and maintenance of cancer stem cells (CSC) subpopulation in primary tumors, reduction of CTC and the likelihood of metastatic spread, and prevention of tumor recurrence through inhibition of CSC tumorigenic and metastatic potential.